A patient on DDAVP for primary enuresis should be monitored for which electrolyte abnormality?

Prepare effectively for the Physician Assistant Clinical Knowledge Rating and Assessment Tool (PACKRAT) 1 Exam with comprehensive resources, flashcards, and detailed explanations. Ace your test with ease!

Multiple Choice

A patient on DDAVP for primary enuresis should be monitored for which electrolyte abnormality?

Explanation:
Desmopressin (DDAVP) used for nocturnal enuresis acts like vasopressin, promoting water reabsorption in the kidneys by increasing aquaporin-2 channels in the collecting ducts. This can lead to excess water in the body and a dilution of serum sodium, causing hyponatremia. In children, hyponatremia can range from mild to serious, with symptoms that may include headache, nausea, confusion, or seizures if severe. To minimize risk, use the lowest effective dose and limit fluid intake around dosing; monitor sodium levels if there are symptoms or if fluid intake is high. Hyponatremia is the concern here; the other electrolyte abnormalities are not typically associated with DDAVP use.

Desmopressin (DDAVP) used for nocturnal enuresis acts like vasopressin, promoting water reabsorption in the kidneys by increasing aquaporin-2 channels in the collecting ducts. This can lead to excess water in the body and a dilution of serum sodium, causing hyponatremia. In children, hyponatremia can range from mild to serious, with symptoms that may include headache, nausea, confusion, or seizures if severe. To minimize risk, use the lowest effective dose and limit fluid intake around dosing; monitor sodium levels if there are symptoms or if fluid intake is high. Hyponatremia is the concern here; the other electrolyte abnormalities are not typically associated with DDAVP use.

More Multiple Choice Questions
Subscribe

Get the latest from Passetra

You can unsubscribe at any time. Read our privacy policy